Comparative efficacy of everolimus versus fulvestrant for hormone-receptor–positive (HR+) advanced breast cancer (ABC) following progression/recurrence after first-line treatment: A network meta-analysis.
Thomas Denis Bachelot
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Guy Heinrich Maria Jerusalem
Consultant or Advisory Role - Novartis
Maria Cikalo
Research Funding - Novartis
Rachael McCool
Research Funding - Novartis
Sarah King
Research Funding - Novartis
Steven Duffy
Research Funding - Novartis
Julie Glanville
Research Funding - Novartis
Danielle Varley
Research Funding - Novartis
Jie Zhang
Employment or Leadership Position - Novartis